About Convergent Therapeutics
Convergent Therapeutics is a Healthcare company based in United States founded in 2020 by Philip Kantoff. Cancer therapeutics are developed using dual-targeted radionuclide therapy. Convergent Therapeutics has raised $130 million across 2 funding rounds from investors including Orbimed, RA Capital and Novo Holdings. The company has 4 employees. Its chief executive, as recorded, is Philip Kantoff. Convergent Therapeutics offers products and services including CONV01-Ξ± and Radioantibodies. Its focus areas include Life Sciences, Oncology, Drugs and Prostate Cancer. Its legal entity is CONVERGENT THERAPEUTICS, INC. Its competitors include Radionetics, Madison Vaccines and Emtora Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Convergent Therapeutics was founded in 2020 in the United States and operates within the biotechnology sector. Focus is placed on developing treatments for cancer through a proprietary approach involving dual-targeted radionuclide therapy. This method is applied to create CONV01-α, in which a monoclonal antibody is conjugated with actinium-225 to deliver radioisotopes specifically to prostate cancer cells.
- Headquarters United States
- Employees 4
- Founders Philip Kantoff
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website convergentrx.com
- Social LinkedIn
- Legal Name Convergent Therapeutics, Inc.
- Total Equity Funding$130M (USD)
in 2 rounds
- Latest Funding Round$40M (USD), Series A
Jul 2024
- InvestorsOrbimed
& 2 more
- Employee Count4
Products & Services of Convergent Therapeutics
Convergent Therapeutics offers a comprehensive portfolio of products and services, including CONV01-α and Radioantibodies.
Targeted therapy using alpha radioantibodies for prostate cancer treatment.
Antibodies with alpha-emitting payloads for precise cancer cell targeting.
Funding Insights of Convergent Therapeutics
Convergent Therapeutics has successfully raised a total of $130M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130M
- Total Rounds 2
- Last Round Series A β $40M
- First Round $90M
(Apr 2023)
- Investors Count 3
All 2 funding rounds of Convergent Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $40M | Series A | β | β | |
| Apr 2023 | $90M | Series A | β | Orbimed, RA Capital Management | β |
3 investors in total: 3 institutional.
Investors in Convergent Therapeutics
Convergent Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, RA Capital and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Convergent Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Convergent Therapeutics
9 people are tracked at Convergent Therapeutics (8 in leadership, 1 in team); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Philip Kantoff | Co-Founder & CEO | Leadership |
Michele Connors Scarlata | Executive Administrative Partner | Leadership |
Anusha Ramachandran | Director, CMC Operations | Leadership |
Caitlyn Harvey | Vp, Head Of CMC | Leadership |
Kyu Jun Son | Senior Director Corporate Development | Leadership |
Jillian Curiale | Senior Director, Finance | Leadership |
Kevin Zikaras | Vice President, Clinical Development Operations | Leadership |
Eric Sullivan | Chief Financial Officer | Leadership |
Nicole Schreiber | Program Lead | Team |
Complete people profiles for Convergent Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Convergent Therapeutics
3 dated milestones of Convergent Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Convergent Therapeutics is founded.
- Funding First funding round of $90.0M.
- Funding Latest funding round, Series A, of $40.0M.
Competitors of Convergent Therapeutics
Convergent Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Radionetics, Madison Vaccines and Emtora Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| radionetics.com | 2021 | San Diego, United States | $136.71M | Peptide-targeted radiopharmaceuticals for cancer treatment are developed. | ||
| madisonvaccines.com | 2012 | Madison, United States | $18M | Immunotherapies for prostate cancer treatment are developed. | ||
| emtorabio.com | 2009 | San Antonio, United States | $2.5M | Reformulated therapies for cancers and age-related disorders are developed. |
Detailed competitors of Convergent Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Convergent Therapeutics
The website of Convergent Therapeutics (convergentrx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 12% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Convergent Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Convergent Therapeutics
Complete news archive for Convergent Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Convergent Therapeutics
Convergent Therapeutics was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Convergent Therapeutics is headquartered in United States.
Philip Kantoff is the CEO of Convergent Therapeutics, as recorded in our data. They have also founded this company.
Convergent Therapeutics is a funded company, having raised a total of $130M across 2 funding rounds to date. The company's 1st funding round was a Series A of $90M, raised on Apr 2023.
Convergent Therapeutics has 4 employees.
Convergent Therapeutics was founded in 2020 in the United States and operates within the biotechnology sector. Focus is placed on developing treatments for cancer through a proprietary approach involving dual-targeted radionuclide therapy. This method is applied to create CONV01-Ξ±, in which a monoclonal antibody is conjugated with actinium-225 to deliver radioisotopes specifically to prostate cancer cells.
Convergent Therapeutics's top competitors include Radionetics, Emtora Biosciences and Madison Vaccines.
Convergent Therapeutics offers CONV01-Ξ± and Radioantibodies.
Convergent Therapeutics has 3 investors. Key investors include Orbimed, RA Capital, and Novo Holdings.
Convergent Therapeutics operates through Convergent Therapeutics, Inc..